Skip to main content
OpenTrials

Clinical trial condition

Metastatic/Locally Advanced Poorly Differentiated NEC

Explore clinical trials studying Metastatic/Locally Advanced Poorly Differentiated NEC. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study
Refine in advanced search Browse all conditions

Metastatic/Locally Advanced Poorly Differentiated NEC trial results

Recruiting

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

NCT07016230

Conditions
Metastatic/Locally Advanced Poorly Differentiated NEC, Metastatic/Locally Advanced Small-Cell Lung Cancer, Neoplasm Metastasis, +4 more
Locations
  • Gustave Roussy Villejuif, France
  • Institut Bergonié Bordeaux, France
  • Centre Antoine Lacassagne Nice, France
View Trial Details

Related conditions